US EditionPublished • loading... • Updated
Butantan Establishes Partnership to Develop New Rabies Vaccine.
Summary by Poder360
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
The Butantan Institute, an agency linked to the São Paulo State Health Secretariat, has signed a technology licensing and collaboration agreement with Replicate Bioscience for the development and commercialization of a self-replicating messenger RNA vaccine for pre- and post-exposure prophylaxis against rabies. The biotech company, based in San Diego, California (USA), created a self-replicating RNA (srRNA) platform for the development of vaccin…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
